Literature DB >> 3354991

Accumulation of platelets and eosinophils in baboon lung after paf-acether challenge. Inhibition by ketotifen.

B Arnoux1, A Denjean, C P Page, D Nolibe, J Morley, J Benveniste.   

Abstract

Intratracheal administration of platelet-activating factor (paf-acether) induced transient bronchoconstriction in baboons. Using an automated isotopic monitoring system, we found that intratracheal administration of paf-acether also elicited transient accumulation of platelets labeled with 111In oxine within the pulmonary vasculature after the increase in maximal peak inspiratory pressure. Bronchoalveolar eosinophilia were inhibited by prophylactic administration of the antiasthma drug ketotifen but not by pyribenzamine, suggesting that the effects of ketotifen are unrelated to H-1 receptor antagonism. Platelet accumulation was not affected by ketotifen or pyribenzamine. This study suggests that paf-acether may be a mediator of the eosinophil recruitment in bronchial asthma and that inhibition of this phenomenon by ketotifen may contribute to the therapeutic efficacy of this drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3354991     DOI: 10.1164/ajrccm/137.4.855

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  17 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  The accumulation of 111In-eosinophils induced by inflammatory mediators, in vivo.

Authors:  L H Faccioli; S Nourshargh; R Moqbel; F M Williams; R Sehmi; A B Kay; T J Williams
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

3.  Effects of platelet-activating factor on vascular permeability and granulocyte recruitment in the rat trachea.

Authors:  J J Brokaw; D M Prow; C M Kirsch; G W White
Journal:  Lung       Date:  1991       Impact factor: 2.584

4.  Eosinophil chemotactic activity of topical PAF on the human nasal mucosa.

Authors:  H Klementsson; M Andersson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Antigen induces leucopenia in non-immunised guinea-pigs injected with platelets from actively sensitized animals.

Authors:  M Pretolani; J Randon; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

6.  Eosinophil accumulation in pulmonary airways of guinea-pigs induced by exposure to an aerosol of platelet-activating factor: effect of anti-asthma drugs.

Authors:  S Sanjar; S Aoki; K Boubekeur; I D Chapman; D Smith; M A Kings; J Morley
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

7.  Platelet activating factor and tracheobronchial respiratory glycoconjugate release in feline and human explants: involvement of the lipoxygenase pathway.

Authors:  J D Lundgren; M Kaliner; C Logun; J H Shelhamer
Journal:  Agents Actions       Date:  1990-06

Review 8.  Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.

Authors:  S M Grant; K L Goa; A Fitton; E M Sorkin
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

9.  Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.

Authors:  R Korth; M Hirafuji; C L Keraly; D Delautier; J Bidault; J Benveniste
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

10.  Mechanism of action of platelet activating factor in the pulmonary circulation: an investigation using a novel isotopic system in rabbit isolated lung.

Authors:  J P Seale; S Nourshargh; P G Hellewell; T J Williams
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.